Tourmaline Bio (TRML) Price & Analysis

Compare

576 Followers

TRML Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.56 - $47.79

Previous CloseN/A

Volume43.44K

Average Volume (3M)1.34M

Market Cap

$1.23B

Enterprise Value$172.73M

Total Cash (Recent Filing)$239.23M

Total Debt (Recent Filing)$145.00K

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Nov 06, 2025

EPS Estimate

-0.96

Last Dividend Ex-Date

Oct 20, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.90

Shares Outstanding25,692,268

10 Day Avg. Volume1,345,330

30 Day Avg. Volume1,342,670

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.14

Enterprise Value/Revenue4.32K

Enterprise Value/Gross Profit-86.37K

Enterprise Value/Ebitda-1.69

Forecast

1Y Price Target

$47.94

Price Target Upside0.40% Upside

Rating ConsensusHold

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

AcquisitionNovartis has a definitive agreement to acquire TRML for approximately $1.4 billion, reflecting a strong valuation of the company.

Clinical Trial ResultsPositive topline data from the Phase 2 TRANQUILITY study of Tourmaline's lead asset, pacibekitug, shows statistically significant reductions in inflammation markers.

Product PotentialPacibekitug is a fully human monoclonal antibody with potential best-in-class properties, selectively binding to interleukin-6, a key proinflammatory cytokine involved in many autoimmune and inflammatory disorders.

Bears Say

Acquisition RisksRisks include failure of pacibekitug in clinical trials, regulatory approval, commercial success, and failure to complete the acquisition.

Stock Rating DowngradeThe stock rating for TRML has been downgraded to Market Perform from Outperform.

Tourmaline Bio News

Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis

Swiss giant drug producer Novartis ($NVS) has found a new destination for its recent partnership spree. On Monday,...

11d ago

NVS

ARWR

Tourmaline Bio downgraded to Market Perform from Outperform at BMO Capital

BMO Capital analyst Kostas Biliouris downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a price target...

12d ago

TRML

Tourmaline Bio downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Tourmaline Bio (TRML) to Neutral from Overweight with a price target of $48, down from...

15d ago

TRML

Tourmaline Bio downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen downgraded Tourmaline Bio (TRML) to Neutral from Buy with a price target of...

16d ago

TRML

Tourmaline Bio downgraded to Hold from Buy at Truist

Truist analyst Srikripa Devarakonda downgraded Tourmaline Bio (TRML) to Hold from Buy with a price target of $48,...

17d ago

TRML

Tourmaline Bio downgraded to Neutral from Buy at Chardan

Chardan downgraded Tourmaline Bio (TRML) to Neutral from Buy with a $48 price target after the company agreed...

17d ago

TRML

Tourmaline Bio downgraded to Hold from Buy at Jefferies

Jefferies downgraded Tourmaline Bio (TRML) to Hold from Buy with a price target of $47.50, down from $64,...

17d ago

TRML

Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz

Stocks were mostly unchanged near noon as the market rally stalls following last week’s move to record highs....

17d ago

Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital

LifeSci Capital analyst Rami Katkhuda downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a $48 price...

17d ago

TRML

Tourmaline Bio downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Yatin Suneja downgraded Tourmaline Bio (TRML) to Neutral from Buy after Novartis (NVS) announced a deal...

17d ago

TRML

Tourmaline Bio downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded Tourmaline Bio (TRML) to Neutral from Outperform with an unchanged $48 price target after the company...

17d ago

TRML

Novartis Seals $1.4B Deal with Tourmaline Bio (TRML) to Bolster Heart Disease Portfolio

Novartis ($NVS), the Swiss pharma giant, said on Tuesday it will acquire Tourmaline Bio ($TRML) for $48 per...

17d ago

NVS

TRML

Hold Rating Issued Amid Novartis’ Acquisition of Tourmaline Bio

BMO Capital analyst Kostas Biliouris downgraded the rating on Tourmaline Bio to a Hold today, setting a price...

12d ago

TRML

Tourmaline Bio Updates Executive Severance Plan

The latest announcement is out from Tourmaline Bio ( ($TRML) ). Tourmaline Bio, Inc. announced amendments to its...

14d ago

TRML

TRML FAQ

What was Tourmaline Bio’s price range in the past 12 months?

Tourmaline Bio lowest stock price was $11.56 and its highest was $47.79 in the past 12 months.

What is Tourmaline Bio’s market cap?

Tourmaline Bio’s market cap is $1.23B.

When is Tourmaline Bio’s upcoming earnings report date?

Tourmaline Bio’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.

How were Tourmaline Bio’s earnings last quarter?

Tourmaline Bio released its earnings results on Aug 13, 2025. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.923 by $0.023.

Is Tourmaline Bio overvalued?

According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tourmaline Bio pay dividends?

Tourmaline Bio pays a Notavailable dividend of $15.118 which represents an annual dividend yield of N/A. See more information on Tourmaline Bio dividends here

What is Tourmaline Bio’s EPS estimate?

Tourmaline Bio’s EPS estimate is -0.96.

How many shares outstanding does Tourmaline Bio have?

Tourmaline Bio has 25,692,268 shares outstanding.

What happened to Tourmaline Bio’s price movement after its last earnings report?

Tourmaline Bio reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.923. Following the earnings report the stock price went up 3.445%.

Which hedge fund is a major shareholder of Tourmaline Bio?

Currently, no hedge funds are holding shares in TRML

Tourmaline Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.62%

Trailing 12-Months

Asset Growth

-21.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Tourmaline Bio (TRML) Earnings & Revenues

Historic Earnings Reports

TRML Stock 12 Month Forecast

Average Price Target

$47.94

▲(0.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","49":"$49","21.25":"$21.3","30.5":"$30.5","39.75":"$39.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,21.25,30.5,39.75,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,25.44923076923077,27.32846153846154,29.20769230769231,31.086923076923078,32.966153846153844,34.84538461538462,36.72461538461538,38.603846153846156,40.48307692307692,42.362307692307695,44.24153846153846,46.12076923076923,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,25.444615384615386,27.31923076923077,29.193846153846152,31.068461538461538,32.94307692307692,34.817692307692305,36.69230769230769,38.566923076923075,40.44153846153846,42.316153846153846,44.19076923076923,46.065384615384616,{"y":47.94,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,25.41076923076923,27.251538461538463,29.092307692307692,30.933076923076925,32.77384615384615,34.614615384615384,36.45538461538462,38.29615384615384,40.136923076923075,41.97769230769231,43.818461538461534,45.65923076923077,{"y":47.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >